New concepts in the immunopathogenesis of multiple sclerosis

Nature Reviews Neuroscience

Volumn 3, Issue 4, 2002, Pages 291-301

  Hemmer, Bernhard ^a   Archelos, Juan J ^b   Hartung, Hans Peter ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; T LYMPHOCYTE;

B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; PREVALENCE; T-LYMPHOCYTES;

EID: 0036546066     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn784     Document Type: Article

References (135)

1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple sclerosis. N. Engl. J. Med. 343, 938-952 (2000).
2. Kremenchutzky, M. et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive- relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 122, 1941-1950 (1999).
3. Miller, D. H., Grossman, R. I., Reingold, S. C. & McFarland, H. F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121, 3-24 (1998).
4. Losseff, N. A. et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119, 2009-2019 (1996).
5. Fox, N. C. et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54, 807-812 (2000).
6. Compston, A. Genetic epidemiology of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 62, 553-561 (1997).
7. Ebers, G. C., Sadovnick, A. D. & Risch, N. J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377, 150-151 (1995).
8. Ebers, G. C. & Dyment, D. A. Genetics of multiple sclerosis. Semin. Neurol. 18, 295-299 (1998).
9. Oksenberg, J. R., Baranzini, S. E., Barcellos, L. F. & Hauser, S. L. Multiple sclerosis: genomic rewards. J. Neuroimmunol. 113, 171-184 (2001).
10. Chapman, J. et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 56, 312-316(2001).
11. Fazekas, F et al. Apolipoprotein E s4 is associated with rapid progression of multiple sclerosis. Neurology 57, 853-857 (2001).
12. Olerup, O. & Hillert, J. HLA class Il-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38, 1-15 (1991).
13. Sibley, W. A., Bamford, C. R. & Clark, K. Clinical viral infections and multiple sclerosis. Lancet 1, 1313-1315 (1985).
14. Gale, C. R. & Martyn, C. N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425-448 (1995).
15. Lauer, K. The risk of multiple sclerosis in the U. S. A. in relation to sociogeographic features: a factor-analytic study. J. Clin. Epidemiol. 47, 43-48 (1994).
16. Kurtzke, J. F. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol. Sci. 21, 383-403 (2000).
17. Lassmann, H., Raine, C. S., Antel, J. & Prineas, J. W. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J. Neuroimmunol. 86, 213-217 (1998).
18. Remlinger, P. Les paralysies du traitement antirabique. Ann. Institut Pasteur 55, 35-68 (1928).
19. Rivers, T. M., Sprunt, D. H. & Gerry, B. P Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58, 39-53 (1933).
20. Wekerle, H., Kojima, K., Lannes-Vieira, J., Lassmann, H. & Linington, C. Animal models. Ann. Neurol. 36, S47-S53 (1994).
21. Paterson, P. Y. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J. exp. Med. 111, 119-135 (1960).
22. Zamvil, S. S. & Steinman, L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579-621 (1990).
23. Rocken, M., Racke, M. & Shevach, E. M. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today 17, 225-231 (1996).
24. Panitch, H. S., Hirsch, R. L., Schindler, J. & Johnson, K. P. Treatment of multiple sclerosis with γ-interferon: exacerbations associated with activation of the immune system. Neurology 37, 1097-1102 (1987).
25. Genain, C. P., Cannella, B., Hauser, S. L. & Raine, C. S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med. 5, 170-175 (1999).
26. Reindl, M. et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122, 2047-2056 (1999).
27. Cross, A. H. MS: the return of the B cell. Neurology 54, 1214-1215 (2000).
28. Martin, R., McFarland, H. F. & McFarlin, D. E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10, 153-187 (1992).
29. O'Connor, K. C., Bar-Or, A. & Hafler, D. A. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21, 81-92 (2001).
30. Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
31. Hemmer, B. et al. Identification of high potency microbial and self ligands for a human autoreactive class ll-restricted T cell clone. J. Exp. Med. 185, 1651-1659 (1997).
32. Benoist, C. & Mathis, D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nature Immunol. 2, 797-801 (2001).
33. Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Rev. Immunol. 2, 85-95 (2002).
34. Hafler, D. A., Saadeh, M. G., Kuchroo, V. K., Milford, E. & Steinman, L. TCR usage in human and experimental demyelinating disease. Immunol. Today 17, 152-159 (1996).
35. Archelos, J. J., Storch, M. K. & Hartung, H. P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47, 694-706 (2000).
36. Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85, 299-302 (1996).
37. Owens, T., Wekerle, H. & Antel, J. Genetic models for CNS inflammation. Nature Med. 7, 161-166 (2001).
38. Willenborg, D. O., Fordham, S., Bernard, C. C., Cowden, W. B. & Ramshaw, I. A. IFN-γ plays a critical down- regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157, 3223-3227 (1996).
39. Ferber, I. A. et al. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156, 5-7 (1996).
40. Furlan, R. et al. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167, 1821-1829 (2001).
41. Bettelli, E. et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299-3306 (1998).
42. Frei, K. et al. Tumor necrosis factor a and lymphotoxin a are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185, 2177-2182 (1997).
43. Sean, R. D. et al. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor- deficient, mice. J. Exp. Med. 187, 1517-1528 (1998).
44. Liu, J. et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med. 4, 78-83 (1998).
45. Kassiotis, G., Pasparakis, M., Kollias, G. & Probert, L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29, 774-780 (1999).
46. Steinman, L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med. 185, 2039-2041 (1997).
47. Brocke, S. et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379, 343-346 (1996).
48. Lafaille, J. J. et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186, 307-312 (1997).
49. Cannella, B. & Raine, C. S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37, 424-435 (1995).
50. Baranzini, S. E. et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 165, 6576-6582 (2000).
51. Sun, D. et al. Myelin antigen-specific CD8+T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166, 7579-7587 (2001).
52. Huseby, E. S. et al. A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J. Exp. Med. 194, 669-676 (2001).
53. Wolf, S. D., Dittel, B. N., Hardardottir, F. & Janeway, C. A. Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184, 2271-2278 (1996).
54. Linington, C., Bradl, M., Lassmann, H., Brunner, C. & Vass, K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130, 443-454 (1988).
55. Becher, B., Durell, B. G., Miga, A. V., Hickey, W. F. & Noelle, R. J. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193, 967-974 (2001).
56. Genain, C. P. et al. Late complications of immune deviation therapy in a nonhuman primate. Science 274, 2054-2057 (1996).
57. van Oosten, B. W. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531-1534 (1996).
58. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo- controlled multicenter study. Neurology 53, 457-465 (1999).
59. van Oosten, B. W. et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial. Neurology 49, 351-357 (1997).
60. Hohlfeld, R. & Wiendl, H. The ups and downs of multiple sclerosis therapeutics. Ann. Neurol. 49, 281-284 (2001).
61. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167-1175 (2000).
62. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nature Med. 6, 1176-1182 (2000).
63. Stohlman, S. A. & Hinton, D. R. Viral induced demyelination. Brain Pathol. 11, 92-106 (2001).
64. Haring, J. & Perlman, S. Mouse hepatitis virus. Curr. Opin. Microbiol. 4, 462-466 (2001).
65. + T cells. J. Immunol. 160, 2896-2904 (1998).
66. Lin, M. T., Hinton, D. R., Marten, N. W., Bergmann, C. C. & Stohlman, S. A. Antibody prevents virus reactivation within the central nervous system. J. Immunol. 162, 7358-7368 (1999).
67. Ramakrishna, C., Stohlman, S. A., Atkinson, R. D., Shlomchik, M. J. & Bergmann, C. C. Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells. J. Immunol. 168, 1204-1211 (2002).
68. Wang, F. I., Stohlman, S. A. & Fleming, J. O. Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. J. Neuroimmunol. 30, 31-41 (1990).
69. Dandekar, A. A., Wu, G. F, Pewe, L. & Perlman, S. Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J. Virol. 75, 6115-6120 (2001).
70. Soldan, S. S. et al. Association of human herpesvirus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med. 3, 1394-1397 (1997).
71. Taus, C. et al. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 101, 224-228 (2000).
72. Sriram, S. et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann. Neurol. 46, 6-14 (1999).
73. Gieffers, J. et al. Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann. Neurol. 49, 585-589 (2001).
74. Ascherio, A. et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083-3088 (2001).
75. Allan, S. M. & Rothwell, N. J. Cytokines and acute neurodegeneration. Nature Rev. Neurosci. 2, 734-744 (2001).
76. del Zoppo, G. et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain PatioL 10, 95-112 (2000).
77. Barone, F. C. & Feuerstein, G. Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19, 819-834 (1999).
78. Nguyen, M. H., Julien, J.-P & Rivest, S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nature Rev. Neurosci. 3, 216-228 (2002).
79. Schmied, M. et al. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Aim. J. PaH 143, 446-452 (1993).
80. Tabi, Z., McCombe, P. A. & Pender, M. P Apoptotic elimination of Vβ 8. 2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of Vβ 8. 2+ encephalitogenic T cells. Eur. J. Immunol. 24, 2609-2617 (1994).
81. Gold, R., Hartung, H. P. & Lassmann, H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune- defense mechanisms. Trends Neurosci. 20, 399-404 (1997).
82. Kabat, E. A., Moore, D. H. & Landow, H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J. Clin. Invest. 21, 571-577 (1942).
83. Losy, J., Mehta, P. D. & Wisniewski, H. M. Identification of IgG subclasses' oligoclonal bands in multiple sclerosis CSF Acta Neurol. Scand. 82, 4-8 (1990).
84. Greve, B., Magnusson, C. G., Melms, A. & Weissert, R. Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis. J. Neuroimmunol. 121, 120-125 (2001).
85. Walsh, M. J. & Tourtellotte, W. W. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J. Exp. Med. 163, 41-53 (1986).
86. Qin, Y et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102, 1045-1050 (1998).
87. Baranzini, S. E. et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163, 5133-5144 (1999).
88. Colombo, M. et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164, 2782-2789 (2000).
89. Owens, G. P, Burgoon, M. P., Anthony, J., Kleinschmidt- DeMasters, B. K. & Gilden, D. H. The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin. Immunol. 98, 258-263 (2001).
90. Smith-Jensen, T. et al. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 54, 1227-1232 (2000).
91. Oksenberg, J. R. et al. Limited heterogeneity of rearranged T-cell receptor V a transcripts in brains of multiple sclerosis patients. Nature 345, 344-346 (1990).
92. Babbe, H. et al. Clonal expansions of CD8+T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393-404 (2000).
93. +T cells in the cerebrospinal fluid from multiple sclerosis patients. Brain 125, 538-550 (2002).
94. Lucchinetti, C., Bruck, W. & Noseworthy, J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 14, 259-269 (2001).
95. Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
96. Cepok, S. et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124, 2169-2176 (2001).
97. Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med. 6, 67-70 (2000).
98. Scolding, N. J. & Franklin, R. J. Remyelination in demyelinating disease. Baillieres Clin. Neurol. 6, 525-548 (1997).
99. Levine, J. M., Reynolds, R. & Fawcett, J. W. The oligodendrocyte precursor cell in health and disease. Trends Neurosci. 24, 39-47 (2001).
100. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18, 601-609 (1998).
101. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346, 165-173 (2002).
102. Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
103. Kornek, B. et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157, 267-276 (2000).
104. Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123, 1174-1183 (2000).
105. Neumann, H., Cavalie, A., Jenne, D. E. & Wekerle, H. Induction of MHC class I genes in neurons. Science 269, 549-552 (1995).
106. Jurewicz, A., Biddison, W E. & Antel, J. P. MHC class I- restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160, 3056-3059 (1998).
107. Medana, I. et al. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J. Immunol. 167, 674-681 (2001).
108. Medana, I., Martinic, M. A., Wekerle, H. & Neumann, H. Transection of major histocompatibility complex class I- induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159, 809-815 (2001).
109. Cortese, I. et al. CSF-enriched antibodies do not share specificities among MS patients. Multiple Sclerosis4, 118-123 (1998).
110. Niehaus, A. et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol. 48, 362-371 (2000).
111. Foulds, K. E. et al. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168, 1528-1532 (2002).
112. Kerschensteiner, M. et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189, 865-870 (1999).
113. Bieber, A. J., Warrington, A., Pease, L. R. & Rodriguez, M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci. 24, 39-44 (2002).
114. Gilden, D. H. et al. Molecular immunologic strategies to identify antigens and B-cell responses unique to multiple sclerosis. Arch. Neurol. 58, 43-48 (2001).
115. Burgoon, M. P, Owens, G. P., Carlson, S., Maybach, A. L. & Gilden, D. H. Antigen discovery in chronic human inflammatory central nervous system disease: panning phage-displayed antigen libraries identifies the targets of central nervous system-derived IgG in subacute sclerosing panencephalitis. J. Immunol. 167, 6009-6014 (2001).
116. Hiemstra, H. S. et al. The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. Proc. Natl Acad. Sci. USA 94, 10313-10318 (1997).
117. Hemmer, B. et al. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nature Med. 5, 1375-1382 (1999).
118. Holler, P D. et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl Acad. Sci. USA 97, 5387-5392 (2000).
119. Whitney, L. W. et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46, 425-428 (1999).
120. Chabas, D. et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731-1735 (2001).
121. Noseworthy, J. H., Gold, R. & Hartung, H. P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr. Opin. Neurol. 12, 279-293 (1999).
122. Davis, M. M. et al. Ligand recognition by αβ T-cell receptors. Annu. Rev. Immunol. 16, 523-544 (1998).
123. Lanzavecchia, A. & Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 106, 263-266 (2001).
124. Mosmann, T. R. & Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146 (1996).
125. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
126. Calame, K. L. Plasma cells: finding new light at the end of B-cell development. Nature Immunol. 2, 1103-1108 (2001).
127. Aloisi, F. Immune function of microglia. Glia 36, 165-179 (2001).
128. Cserr, H. F. & Knopf, P. M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507-512 (1992).
129. Knopf, P. M. et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol. 161, 692-701 (1998).
130. Archelos, J. J. & Hartung, H. P. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol. Med. Today 3, 310-321 (1997).
131. Archelos, J. J., Previtali, S. C. & Hartung, H. P. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22, 30-38 (1999).
132. Kieseier, B. C., Seifert, T., Giovannoni, G. & Hartung, H. P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53, 20-25 (1999).
133. Flugel, A. et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14, 547-560 (2001).
134. Weller, R. O., Engelhardt, B. & Phillips, M. J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 6, 275-288 (1996).
135. The Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of genomic screens in multiple sclerosis. Multiple Sclerosis 7, 3-11 (2001).